Cargando…

Homeostasis in the Gut Microbiota in Chronic Kidney Disease

The gut microbiota consists of trillions of microorganisms, fulfilling important roles in metabolism, nutritional intake, physiology and maturation of the immune system, but also aiding and abetting the progression of chronic kidney disease (CKD). The human gut microbiome consists of bacterial speci...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhargava, Shruti, Merckelbach, Erik, Noels, Heidi, Vohra, Ashima, Jankowski, Joachim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9610479/
https://www.ncbi.nlm.nih.gov/pubmed/36287917
http://dx.doi.org/10.3390/toxins14100648
_version_ 1784819279556771840
author Bhargava, Shruti
Merckelbach, Erik
Noels, Heidi
Vohra, Ashima
Jankowski, Joachim
author_facet Bhargava, Shruti
Merckelbach, Erik
Noels, Heidi
Vohra, Ashima
Jankowski, Joachim
author_sort Bhargava, Shruti
collection PubMed
description The gut microbiota consists of trillions of microorganisms, fulfilling important roles in metabolism, nutritional intake, physiology and maturation of the immune system, but also aiding and abetting the progression of chronic kidney disease (CKD). The human gut microbiome consists of bacterial species from five major bacterial phyla, namely Firmicutes, Bacteroidetes, Actinobacteria, Proteobacteria, and Verrucomicrobia. Alterations in the members of these phyla alter the total gut microbiota, with a decline in the number of symbiotic flora and an increase in the pathogenic bacteria, causing or aggravating CKD. In addition, CKD-associated alteration of this intestinal microbiome results in metabolic changes and the accumulation of amines, indoles and phenols, among other uremic metabolites, which have a feedforward adverse effect on CKD patients, inhibiting renal functions and increasing comorbidities such as atherosclerosis and cardiovascular diseases (CVD). A classification of uremic toxins according to the degree of known toxicity based on the experimental evidence of their toxicity (number of systems affected) and overall experimental and clinical evidence was selected to identify the representative uremic toxins from small water-soluble compounds, protein-bound compounds and middle molecules and their relation to the gut microbiota was summarized. Gut-derived uremic metabolites accumulating in CKD patients further exhibit cell-damaging properties, damage the intestinal epithelial cell wall, increase gut permeability and lead to the translocation of bacteria and endotoxins from the gut into the circulatory system. Elevated levels of endotoxins lead to endotoxemia and inflammation, further accelerating CKD progression. In recent years, the role of the gut microbiome in CKD pathophysiology has emerged as an important aspect of corrective treatment; however, the mechanisms by which the gut microbiota contributes to CKD progression are still not completely understood. Therefore, this review summarizes the current state of research regarding CKD and the gut microbiota, alterations in the microbiome, uremic toxin production, and gut epithelial barrier degradation.
format Online
Article
Text
id pubmed-9610479
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96104792022-10-28 Homeostasis in the Gut Microbiota in Chronic Kidney Disease Bhargava, Shruti Merckelbach, Erik Noels, Heidi Vohra, Ashima Jankowski, Joachim Toxins (Basel) Review The gut microbiota consists of trillions of microorganisms, fulfilling important roles in metabolism, nutritional intake, physiology and maturation of the immune system, but also aiding and abetting the progression of chronic kidney disease (CKD). The human gut microbiome consists of bacterial species from five major bacterial phyla, namely Firmicutes, Bacteroidetes, Actinobacteria, Proteobacteria, and Verrucomicrobia. Alterations in the members of these phyla alter the total gut microbiota, with a decline in the number of symbiotic flora and an increase in the pathogenic bacteria, causing or aggravating CKD. In addition, CKD-associated alteration of this intestinal microbiome results in metabolic changes and the accumulation of amines, indoles and phenols, among other uremic metabolites, which have a feedforward adverse effect on CKD patients, inhibiting renal functions and increasing comorbidities such as atherosclerosis and cardiovascular diseases (CVD). A classification of uremic toxins according to the degree of known toxicity based on the experimental evidence of their toxicity (number of systems affected) and overall experimental and clinical evidence was selected to identify the representative uremic toxins from small water-soluble compounds, protein-bound compounds and middle molecules and their relation to the gut microbiota was summarized. Gut-derived uremic metabolites accumulating in CKD patients further exhibit cell-damaging properties, damage the intestinal epithelial cell wall, increase gut permeability and lead to the translocation of bacteria and endotoxins from the gut into the circulatory system. Elevated levels of endotoxins lead to endotoxemia and inflammation, further accelerating CKD progression. In recent years, the role of the gut microbiome in CKD pathophysiology has emerged as an important aspect of corrective treatment; however, the mechanisms by which the gut microbiota contributes to CKD progression are still not completely understood. Therefore, this review summarizes the current state of research regarding CKD and the gut microbiota, alterations in the microbiome, uremic toxin production, and gut epithelial barrier degradation. MDPI 2022-09-20 /pmc/articles/PMC9610479/ /pubmed/36287917 http://dx.doi.org/10.3390/toxins14100648 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Bhargava, Shruti
Merckelbach, Erik
Noels, Heidi
Vohra, Ashima
Jankowski, Joachim
Homeostasis in the Gut Microbiota in Chronic Kidney Disease
title Homeostasis in the Gut Microbiota in Chronic Kidney Disease
title_full Homeostasis in the Gut Microbiota in Chronic Kidney Disease
title_fullStr Homeostasis in the Gut Microbiota in Chronic Kidney Disease
title_full_unstemmed Homeostasis in the Gut Microbiota in Chronic Kidney Disease
title_short Homeostasis in the Gut Microbiota in Chronic Kidney Disease
title_sort homeostasis in the gut microbiota in chronic kidney disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9610479/
https://www.ncbi.nlm.nih.gov/pubmed/36287917
http://dx.doi.org/10.3390/toxins14100648
work_keys_str_mv AT bhargavashruti homeostasisinthegutmicrobiotainchronickidneydisease
AT merckelbacherik homeostasisinthegutmicrobiotainchronickidneydisease
AT noelsheidi homeostasisinthegutmicrobiotainchronickidneydisease
AT vohraashima homeostasisinthegutmicrobiotainchronickidneydisease
AT jankowskijoachim homeostasisinthegutmicrobiotainchronickidneydisease